{"api":{"name":"api.sb","description":"Business-as-Code surface for Startups.Studio","home":"https://api.sb","docs":"https://api.sb/docs","version":"1.0.0"},"$context":"https://api.sb/$context","$type":"FoundingHypothesis","$id":"https://api.sb/founding-hypotheses/fh%3Aw2-investigational-new-drug-application-to-fda-submission-regulatory-affairs-mgr-ind-application%3At-bu%3Av1","links":{"self":"https://api.sb/v1/founding-hypotheses/fh%3Aw2-investigational-new-drug-application-to-fda-submission-regulatory-affairs-mgr-ind-application%3At-bu%3Av1","canonical":"https://api.sb/founding-hypotheses/fh%3Aw2-investigational-new-drug-application-to-fda-submission-regulatory-affairs-mgr-ind-application%3At-bu%3Av1","pool":"https://api.sb/v1/founding-hypotheses"},"foundingHypothesis":{"id":"fh:w2-investigational-new-drug-application-to-fda-submission-regulatory-affairs-mgr-ind-application:t-bu:v1","lens":"ManagedWorkflow","type":"founding-hypothesis","click":{"rubricScores":{"C8_lensFit":1,"C7_magicLensFit":1,"C4_competitorHonesty":1,"C6_crossSlotCoherence":1,"C1_customerSpecificity":1,"C2_problemFrictionRealism":1,"C9_killCriteriaAttestability":1,"C3_approachEngineCoverability":1,"C5_differentiationLoservilleEscape":1},"upperRightLoserville":true},"cellRef":{"id":"work-contexts.org.ai/w2-investigational-new-drug-application-to-fda-submission-regulatory-affairs-mgr-ind-application","stableHash":"wcc:regulatory-affairs-mgr:investigational-new-drug-application-to-fda-submission:ind-application:v1"},"problem":{"slotStatement":"The RA Manager burns weeks reconciling Module 2 summaries against Module 3 CMC source documents and Module 4 nonclinical study reports, chasing CRO-supplied PDFs whose numbers drift from the CTD narrative, with no defensible trace from each summary claim back to the study report page that supports it before the IND goes out the door."},"approach":{"oneSentence":"A CTD cross-module reconciliation workbench that validates every Module 2 summary statement against its Module 3/4 source page, flags drift the moment a CRO report is re-versioned, and produces a review-ready citation trace the VP of RA can sign off on before eCTD publishing."},"customer":{"icpShape":"US-based clinical-stage biotech (Series B–C, 50–250 FTE, 1–3 programs in IND-enabling studies) where the buyer is the VP of Regulatory Affairs (signs the tooling PO) and the daily user is the Regulatory Affairs Manager assembling the eCTD IND modules.","beachheadShape":"EarlyMajorityWorkflow — first-time-IND sponsors preparing a single small-molecule or biologic IND under a 30-day FDA clock with no in-house eCTD publishing team."},"archetype":"startup-archetypes.org.ai/ManagedWorkflow-MoneyOnDelivery","beachhead":"EarlyMajorityWorkflow — first-time-IND sponsors preparing a single small-molecule or biologic IND under a 30-day FDA clock with no in-house eCTD publishing team.","competitors":{"substitutes":[{"name":"Veeva Vault RIM / Submissions","category":"incumbent"},{"name":"Lorenz docuBridge eCTD publishing suite","category":"incumbent"},{"name":"Certara GlobalSubmit / Pinnacle 21","category":"adjacent vertical"},{"name":"Contract medical writers + tracked-changes Word review","category":"human alternative"}]},"studioThesis":"T-BU","killThreshold":{"K":11,"M":30,"N":8,"rubricItemSet":["C1_customerSpecificity","C2_problemFrictionRealism","C3_approachEngineCoverability","C4_competitorHonesty","C5_differentiationLoservilleEscape","C6_crossSlotCoherence","C7_magicLensFit","C8_lensFit","C9_killCriteriaAttestability"],"verdictPolicy":"all-load-bearing-pass-and-overall-ge-X","loadBearingItemSet":["C1_customerSpecificity","C2_problemFrictionRealism","C3_approachEngineCoverability","C4_competitorHonesty","C5_differentiationLoservilleEscape","C6_crossSlotCoherence","C9_killCriteriaAttestability"],"verdictPolicyVerbatim":"KILL unless every load-bearing rubric item passes per workbook AND overall pass-rate ≥ 8/9 (CASCADE.md §4 Stage 9 commit threshold)."},"lifecycleState":"Active","differentiation":{"twoByTwo":{"xAxis":"Evidence trace depth (narrative-only summaries ↔ every Module 2 sentence linked to the exact Module 3/4 source-report page and table cell)","yAxis":"Regulatory authority posture (general document QC ↔ IND-specific 21 CFR 312.23 content rules enforced pre-publish)","winningQuadrant":"Per-sentence Module-2-to-source citations enforced against 21 CFR 312.23 content requirements, generating a review-ready trace the VP of RA signs before eCTD hand-off","loservilleEscape":true,"loservilleQuadrant":"Veeva Vault Submissions and Lorenz docuBridge validate eCTD structure and file hygiene but treat Module 2 prose as opaque narrative — no per-claim source linkage and no 312.23 content rule checks, so RA Managers still reconcile by hand in Word."}},"unmetRequirements":[],"pricingArchitecture":"usage-meter"},"actions":{},"options":{},"relationships":{"runtimeUnit":"https://api.sb/v1/runtime-units?startupRef=startup%3Afh%3Aw2-investigational-new-drug-application-to-fda-submission-regulatory-affairs-mgr-ind-application%3At-bu%3Av1","brand":"https://api.sb/v1/brands?startupId=startup%3Afh%3Aw2-investigational-new-drug-application-to-fda-submission-regulatory-affairs-mgr-ind-application%3At-bu%3Av1","listing":"https://api.services/listings?foundingHypothesisRef=fh%3Aw2-investigational-new-drug-application-to-fda-submission-regulatory-affairs-mgr-ind-application%3At-bu%3Av1","cell":"https://api.sb/v1/cells/work-contexts.org.ai/w2-investigational-new-drug-application-to-fda-submission-regulatory-affairs-mgr-ind-application","thesis":"https://api.sb/v1/theses/T-BU"},"meta":{"level":"L0","scopes":[]},"user":{"requestId":"a0575bd90f522e5c","edgeLocation":"a0575bd90f522e5c","geo":{"country":"US"},"ua":{"browser":"Claude"}},"references":{"total":0,"limit":25,"page":1,"links":{"self":"https://api.sb/v1/founding-hypotheses/fh%3Aw2-investigational-new-drug-application-to-fda-submission-regulatory-affairs-mgr-ind-application%3At-bu%3Av1/references"},"items":[]}}